Belgian academic hospital contributing clinical trial infrastructure, immunotherapy expertise, and health economics analysis to European medical research consortia.
Antwerp University Hospital (UZA) is a major Belgian academic medical center that bridges clinical care with translational research. Their H2020 portfolio reveals deep involvement in clinical trials — from immunotherapy for rare cancers to cardiac emergencies and multiple sclerosis treatments — always contributing real patient data and clinical expertise. They also bring health economics evaluation capacity, helping consortia assess the cost-effectiveness of new diagnostics and therapies. More recently, they have become an active node in Europe's infectious disease research preparedness network.
Led clinical work in dendritic cell immunotherapy for mesothelioma (H2020MM04), tolerogenic dendritic cell therapy for multiple sclerosis (RESTORE), and corneal regeneration (ARREST BLINDNESS).
Participated in ND4ID, VALUE-Dx (antimicrobial resistance diagnostics), RECoVER (SARS-CoV-2 emergency response), and ECRAID-Base (European infectious disease research alliance).
Contributed health economics analysis and clinical trial execution across MCDS-Therapy, EURO SHOCK, VALUE-Dx, and EHRA-PATHS.
SLEEP REVOLUTION applies machine learning and deep learning to personalized sleep diagnostics and therapy — a new direction combining clinical expertise with digital health.
TAPAS project trained researchers in automatic processing of pathological speech, bridging clinical speech therapy with speech recognition technology.
EURO SHOCK tested extracorporeal membrane oxygenation for cardiogenic shock; EHRA-PATHS addresses multimorbidity in atrial fibrillation patients.
In 2016–2018, UZA focused on advanced therapies — dendritic cell immunotherapy, regenerative medicine, orphan drug repurposing, and quantitative MRI for brain diseases. From 2019 onward, their portfolio shifted decisively toward infectious disease preparedness (RECoVER, ECRAID-Base, VALUE-Dx) and population-level health challenges like healthcare worker wellbeing, sleep disorders, and multimorbidity in the elderly. This reflects a hospital pivoting from bench-to-bedside experimental treatments toward large-scale clinical research networks and digital health applications.
UZA is moving toward large-scale clinical research networks and AI-assisted diagnostics, making them an increasingly valuable partner for digital health and pandemic preparedness consortia.
UZA consistently joins as a clinical partner or third-party contributor — they have never coordinated an H2020 project, preferring to bring clinical expertise and patient cohorts to consortia led by others. With 266 unique partners across 36 countries, they are well-networked but not a hub; they plug into large multinational consortia (typically 15-30 partners) where a university hospital's clinical data and trial infrastructure are essential. This makes them a reliable, low-maintenance consortium member who delivers clinical validation without seeking the coordination spotlight.
UZA has collaborated with 266 unique partners across 36 countries, indicating broad pan-European reach with connections well beyond Western Europe. Their partnerships span academic hospitals, universities, SMEs in diagnostics, and large clinical research networks.
UZA combines the clinical trial infrastructure of a major academic hospital with genuine research depth in immunotherapy and infectious diseases — not just patient recruitment but active scientific contribution. Their health economics capacity is a differentiator: they can evaluate not just whether a treatment works, but whether it is cost-effective, which is increasingly required by EU funding calls. For consortium builders, UZA offers a Belgian clinical site with regulatory experience, diverse patient populations, and a track record of delivering within large multinational trials.
